Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

INTRODUCTION: Resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies is an emerging clinical problem. The efficacy of anti-EGFR therapies can be influenced by the presence of heregulins (HRGs), which can bind erbB3/4 receptors and can activate alternative signalling pathways. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutcheson, Iain R, Knowlden, Janice M, Hiscox, Steve E, Barrow, Denise, Gee, Julia MW, Robertson, John F, Ellis, Ian O, Nicholson, Robert I
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206726/
https://www.ncbi.nlm.nih.gov/pubmed/17686159
http://dx.doi.org/10.1186/bcr1754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206726/
https://www.ncbi.nlm.nih.gov/pubmed/17686159
http://dx.doi.org/10.1186/bcr1754

Ejemplares similares